210 related articles for article (PubMed ID: 35806362)
1. Combined Analysis of HLA Class II Eplet Mismatch and Tacrolimus Levels for the Prediction of De Novo Donor Specific Antibody Development in Kidney Transplant Recipients.
Lee H; Min JW; Kang H; Lee H; Eum SH; Park Y; Yang CW; Chung BH; Oh EJ
Int J Mol Sci; 2022 Jul; 23(13):. PubMed ID: 35806362
[TBL] [Abstract][Full Text] [Related]
2. Class II Eplet Mismatch Modulates Tacrolimus Trough Levels Required to Prevent Donor-Specific Antibody Development.
Wiebe C; Rush DN; Nevins TE; Birk PE; Blydt-Hansen T; Gibson IW; Goldberg A; Ho J; Karpinski M; Pochinco D; Sharma A; Storsley L; Matas AJ; Nickerson PW
J Am Soc Nephrol; 2017 Nov; 28(11):3353-3362. PubMed ID: 28729289
[TBL] [Abstract][Full Text] [Related]
3. Impact of HLA Eplet Mismatch on De Novo Donor Specific Antibody Formation After Kidney Transplantation.
Yanyiam P; Kantachuvesiri S; Thammanichanond D
Transplant Proc; 2024 Apr; 56(3):515-520. PubMed ID: 38368130
[TBL] [Abstract][Full Text] [Related]
4. HLA-DQ eplet mismatch load may identify kidney transplant patients eligible for tacrolimus withdrawal without donor-specific antibody formation after mesenchymal stromal cell therapy.
Bezstarosti S; Meziyerh S; Reinders MEJ; Voogt-Bakker K; Groeneweg KE; Roelen DL; Kers J; de Fijter JW; Heidt S
HLA; 2023 Jul; 102(1):3-12. PubMed ID: 36841928
[TBL] [Abstract][Full Text] [Related]
5. HLA B eplet mismatches in the context of delayed graft function and low tacrolimus trough levels are risk factors influencing the generation of de novo donor-specific antibodies and acute rejection in the early stage after kidney transplantation.
Gao S; Gong H; Li M; Lan P; Zhang M; Kuang P; Zhang Y; Hu X; Ding C; Li Y; Ding X; Xue W; Zheng J
Transpl Immunol; 2023 Dec; 81():101955. PubMed ID: 37931666
[TBL] [Abstract][Full Text] [Related]
6. Eplet Mismatch Load and
Senev A; Coemans M; Lerut E; Van Sandt V; Kerkhofs J; Daniëls L; Driessche MV; Compernolle V; Sprangers B; Van Loon E; Callemeyn J; Claas F; Tambur AR; Verbeke G; Kuypers D; Emonds MP; Naesens M
J Am Soc Nephrol; 2020 Sep; 31(9):2193-2204. PubMed ID: 32764139
[TBL] [Abstract][Full Text] [Related]
7. Mismatch epitope load predicts de novo-DSA-free survival in pediatric liver transplantation.
Shin S; Lee M; Dente E; Yazigi N; Khan KM; Kaufman SS; Ahn J; Timofeeva OA; Ekong UD
Pediatr Transplant; 2022 Jun; 26(4):e14251. PubMed ID: 35279919
[TBL] [Abstract][Full Text] [Related]
8. Eplet mismatches associated with de novo donor-specific HLA antibody in pediatric kidney transplant recipients.
Charnaya O; Jones J; Philogene MC; Chiang PY; Segev DL; Massie AB; Garonzik-Wang J
Pediatr Nephrol; 2021 Dec; 36(12):3971-3979. PubMed ID: 34100108
[TBL] [Abstract][Full Text] [Related]
9. Donor selection in pediatric kidney transplantation using DR and DQ eplet mismatching: A new histocompatibility paradigm.
Bryan CF; Chadha V; Warady BA
Pediatr Transplant; 2016 Nov; 20(7):926-930. PubMed ID: 27448994
[TBL] [Abstract][Full Text] [Related]
10. Is the level of HLA eplet mismatch a risk factor for graft loss among kidney transplant recipients who have already formed de novo donor specific antibody?
Wen J; Basu A; Bentall A; Henderson N; Dukek B; Gandhi M; Schinstock C
Hum Immunol; 2021 Apr; 82(4):240-246. PubMed ID: 33618904
[TBL] [Abstract][Full Text] [Related]
11. Class II HLA Eplet Mismatch Is a Risk Factor for De Novo Donor-Specific Antibody Development and Antibody-mediated Rejection in Kidney Transplantation Recipients.
Kishikawa H; Kinoshita T; Hashimoto M; Fukae S; Taniguchi A; Yamanaka K; Nakagawa M; Nishimura K
Transplant Proc; 2018 Oct; 50(8):2388-2391. PubMed ID: 30316363
[TBL] [Abstract][Full Text] [Related]
12. The association between human leukocyte antigen eplet mismatches, de novo donor-specific antibodies, and the risk of acute rejection in pediatric kidney transplant recipients.
Sharma A; Taverniti A; Graf N; Teixeira-Pinto A; Lewis JR; Lim WH; Alexander SI; Durkan A; Craig JC; Wong G
Pediatr Nephrol; 2020 Jun; 35(6):1061-1068. PubMed ID: 32065279
[TBL] [Abstract][Full Text] [Related]
13. Eplet mismatch scores and de novo donor-specific antibody development in simultaneous pancreas-kidney transplantation.
Ladowski JM; Mullins H; Romine M; Kloda D; Young C; Hauptfeld-Dolejsek V; Houp J; Locke J
Hum Immunol; 2021 Mar; 82(3):139-146. PubMed ID: 33390268
[TBL] [Abstract][Full Text] [Related]
14. Human leukocyte antigen epitope mismatch loads and the development of de novo donor-specific antibodies in cardiothoracic organ transplantation.
Bedford A; Jervis S; Worthington J; Lowe M; Poulton K
Int J Immunogenet; 2022 Feb; 49(1):30-38. PubMed ID: 34904369
[TBL] [Abstract][Full Text] [Related]
15. A Comparison of HLA Molecular Mismatch Methods to Determine HLA Immunogenicity.
Wiebe C; Kosmoliaptsis V; Pochinco D; Taylor CJ; Nickerson P
Transplantation; 2018 Aug; 102(8):1338-1343. PubMed ID: 29443827
[TBL] [Abstract][Full Text] [Related]
16. HLA class II eplet mismatch load improves prediction of dnDSA development after living donor kidney transplantation.
Tafulo S; Malheiro J; Santos S; Dias L; Almeida M; Martins S; Pedroso S; Mendes C; Lobato L; Castro-Henriques A
Int J Immunogenet; 2021 Feb; 48(1):1-7. PubMed ID: 33145950
[TBL] [Abstract][Full Text] [Related]
17. Urinary CXCL10 specifically relates to HLA-DQ eplet mismatch load in kidney transplant recipients.
San Segundo D; Guiral-Foz SA; Benito-Hernández A; Fernández AR; Arnau A; Valero R; Ramos-Barrón MA; García-Unzueta MT; Gómez-Ortega JM; López-Hoyos M; Ruiz JC; Rodrigo E
Transpl Immunol; 2022 Feb; 70():101494. PubMed ID: 34774739
[TBL] [Abstract][Full Text] [Related]
18. Class II HLA epitope matching-A strategy to minimize de novo donor-specific antibody development and improve outcomes.
Wiebe C; Pochinco D; Blydt-Hansen TD; Ho J; Birk PE; Karpinski M; Goldberg A; Storsley LJ; Gibson IW; Rush DN; Nickerson PW
Am J Transplant; 2013 Dec; 13(12):3114-22. PubMed ID: 24164958
[TBL] [Abstract][Full Text] [Related]
19. HLA-DQ mismatches stimulate de novo donor specific antibodies in heart transplant recipients.
Zhang X; Kransdorf E; Levine R; Patel JK; Kobashigawa JA
Hum Immunol; 2020 Jul; 81(7):330-336. PubMed ID: 32307126
[TBL] [Abstract][Full Text] [Related]
20. Optimal blood levels of (extended-release) tacrolimus in living donor kidney transplantation to prevent de novo donor-specific antibody production: A retrospective cohort study.
Hiramitsu T; Tomosugi T; Futamura K; Okada M; Nishihira M; Goto N; Ichimori T; Narumi S; Kobayashi T; Uchida K; Watarai Y
Int Immunopharmacol; 2021 Feb; 91():107038. PubMed ID: 33388731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
